2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

9:00AM-11:00AM: Abstract Number: 1931

PLCe1 Mediates Cellular Adhesion Downstream of SDF-1 in T Cells

T cell Biology and Targets in Autoimmune Disease Poster I

9:00AM-11:00AM: Abstract Number: 1519

Pleuropulmonary Manifestations in Rheumatoid Arthritis Patients

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1368

PMN Reactivity Contribute to Acute Onset Joint Inflammation By Increasing CXCL8 Production in Joints of RA Patients with Anti-Collagen II Antibodies

Innate Immunity and Rheumatic Disease Poster II

9:00AM-11:00AM: Abstract Number: 1447

Positive Power Doppler Signal Increases the Risk of Clinical Flare of Patients with Juvenile Idiopathic Arthritis in Clinical Remission: A Prospective Study

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters. Juvenile Arthritis and Miscellaneous Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1416

Postoperative Complications Rate in Orthopaedic Surgery Performed in Rheumatic Patients in Use of Biologic Agents

Orthopedics, Low Back Pain and Rehabilitation Poster

9:00AM-11:00AM: Abstract Number: 1943

Potent and Selective Tyk2 Inhibitors Block Th1- and Th17- Mediated Immune Responses and Reduce Disease Progression in Rodent Models of Delayed-Type Hypersensitivity and Psoriasis

T cell Biology and Targets in Autoimmune Disease Poster I

9:00AM-11:00AM: Abstract Number: 1097

Pre-Clinical Development of a Novel, Potent and Selective BTK Inhibitor for Autoimmune Disease and Inflammation Including Arthritis

B cell Biology and Targets in Rheumatolid Arthritis and other Autoimmune Disease Poster

9:00AM-11:00AM: Abstract Number: 1837

Predictability of Musculoskeletal Flares and Hand Deformities in Systemic Lupus Erythematosus By High Resolution Ultrasound : 5-Year Clinical and Imaging Prospective Follow-up Study

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1433

Predicting Response to Osteoarthritis Treatment Based on Patient Reported Outcome Measures and Quantitative Sensory Testing

Pain: Basic and Clinical Aspects Poster

9:00AM-11:00AM: Abstract Number: 1318

Prediction of Large Joint Destruction in Patients with Rheumatoid Arthritis Using FDG-PET/CT: A Prospective Study

Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT

9:00AM-11:00AM: Abstract Number: 1674

Predictive Factors of Persistence in Therapy with Abatacept in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

9:00AM-11:00AM: Abstract Number: 1207

Predictive Utility of Anti- Citrullinated Peptide Antibodies and Rheumatoid Factor – a Retrospective Dataanalysis

Epidemiology and Public Health Poster II: Pathogenesis and Treatment of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 1729

Predictors and Clinical Factors Associated with Change in Spinal Inflammation Assessed on MRI over 2 Years: Data from Tasmanian Ankylosing Spondylitis Study

Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1708

Predictors of Depression Severity in Ankylosing Spondylitis

Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1528

Predictors of Employment, Work Productivity Loss, Activity Impairment, and Regaining Employment in Latinos with Rheumatoid Arthritis in the United States

Rheumatoid Arthritis - Clinical Aspects Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].